Cryptococcosis in renal transplant patients.
First, cryptococcal infections in transplant patients can be readily diagnosed and successfully treated; aggressive, innovative uses of currently available drugs should accomplish this. Second, some drug related toxicity, mostly nephrotoxicity and hematologic, is inevitable, and patients must be carefully monitored so that these effects may be minimized. Third, anti-fungal drug assays are available and can be performed and drug levels should be monitored, with the object of obtaining levels which are both reasonably safe and maximally effective in terms of known in vitro susceptibilities of the offending pathogen.
D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001853:Bone Marrow / Q000187:drug effects; D002986:Clinical Trials as Topic; D003453:Cryptococcosis / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D005260:Female; D005437:Flucytosine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014184:Transplantation, Homologous
D000666:Amphotericin B; D005437:Flucytosine